ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Portfolio Pulse from
ALX Oncology Holdings Inc. will host a virtual event to discuss updated data from their ASPEN-06 Phase 2 trial on January 23, 2025. The trial evaluates the CD47-blocker evorpacept in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
January 21, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ALX Oncology is set to present updated data from its ASPEN-06 Phase 2 trial, which could impact investor sentiment and stock price. The trial focuses on evorpacept for treating HER2-positive gastric cancer.
The announcement of updated trial data is significant for ALX Oncology as it could influence investor perception of the company's progress in cancer treatment. Positive data could lead to a stock price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100